HEALTHVIRGINIA MERCURY
Efforts to reform federal drug pricing program 340B continue with new report, proposed CMS rule
The 340B drug pricing program, designed to provide discounts to hospitals and clinics serving underserved populations, faces scrutiny due to misuse by some providers, including Richmond Community Hospital and Cleveland Clinic, which allegedly exploited the system for profit. Federal officials are proposing reforms via the 340B For Patients Act and a new CMS rule to reduce Medicare payments for 340B drugs.
Mentioned
340B For Patients Acttopic340B Drug Pricing ProgramtopicCenter for Medicare and Medicaid ServicesorganizationBon SecoursorganizationRichmond Community HospitalorganizationCleveland ClinicorganizationSenate Health, Education, Labor and Pensions (HELP) committeeorganizationTim KainepersonVirginiaplace
Related Signal
Adjacent reporting
- A proposed Medicare reimbursement change could reshape hospital drug pricing
- STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals
- Trump administration proposes a rule it says could save Medicare patients $1.1 billion on drugs
- STAT+: Medicare takes another swing at 340B cuts to hospitals
- Trump administration proposes a rule it says could save Medicare patients $1.1 billion on drugs